Vanda Pharmaceuticals (VNDA) : Armistice Capital reduced its stake in Vanda Pharmaceuticals by 1.84% during the most recent quarter end. The investment management company now holds a total of 1,600,000 shares of Vanda Pharmaceuticals which is valued at $20,480,000 after selling 30,000 shares in Vanda Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Vanda Pharmaceuticals makes up approximately 9.21% of Armistice Capital’s portfolio.
Other Hedge Funds, Including , Venbio Select Advisor reduced its stake in VNDA by selling 406,230 shares or 32.22% in the most recent quarter. The Hedge Fund company now holds 854,579 shares of VNDA which is valued at $10,938,611. Vanda Pharmaceuticals makes up approx 3.88% of Venbio Select Advisor’s portfolio.Teacher Retirement System Of Texas boosted its stake in VNDA in the latest quarter, The investment management firm added 267 additional shares and now holds a total of 5,518 shares of Vanda Pharmaceuticals which is valued at $66,933.Swiss National Bank reduced its stake in VNDA by selling 3,300 shares or 4.95% in the most recent quarter. The Hedge Fund company now holds 63,400 shares of VNDA which is valued at $758,264.Columbus Circle Investors reduced its stake in VNDA by selling 38,096 shares or 36.43% in the most recent quarter. The Hedge Fund company now holds 66,478 shares of VNDA which is valued at $795,077. Vanda Pharmaceuticals makes up approx 0.01% of Columbus Circle Investors’s portfolio.
Vanda Pharmaceuticals closed down -0.09 points or -0.59% at $15.29 with 5,61,645 shares getting traded on Thursday. Post opening the session at $15.36, the shares hit an intraday low of $15.05 and an intraday high of $15.476 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Vanda Pharmaceuticals reported $0.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.23 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $-0.22. The company had revenue of $36.02 million for the quarter, compared to analysts expectations of $35.78 million. The company’s revenue was up 30.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon) Fanapt (iloperidone) Tradipitant (VLY-686) Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.